Quick answer
Neuromyelitis optica spectrum disorder is an autoimmune disease of the central nervous system that strikes mostly young women in Asia, and it is on China's first rare disease list. Attacks cause blindness and paralysis, and current treatment suppresses the immune system broadly rather than targeting the mechanism. Qiu Wei and Tang Changyong at the Third Affiliated Hospital of Sun Yat-sen University traced how the disease damages tissue: antibody binding makes astrocytes release complement C3, which switches microglia into an inflammatory state through C3aR and STAT3. Blocking that receptor restored visual and motor function in animal models. The study appeared in Fundamental Research on 18 November 2025 [1][2][5].
Key takeaways
- Published in Fundamental Research, a National Natural Science Foundation of China journal, on 18 November 2025 [1][2].
- Upstream event: NMO-IgG stimulates astrocytes to secrete complement C3, which increases C3aR expression on microglia [1].
- Downstream event: C3-C3aR signalling promotes STAT3 phosphorylation in microglia, amplifying neuroinflammation [1][5].
- Intervention: the C3aR inhibitor SB 290157 improved visual evoked potentials in a rat eye model and motor function in a mouse model [1].
- Follows the team's 2023 work in Molecular Therapy targeting astrocytic C3 [2][3][4].
Why two cell types, not one
NMOSD is defined by antibodies against aquaporin-4 on astrocyte end-feet. That explains the initial injury but not the amplification: a single hit on astrocytes would not produce the waves of inflammation and demyelination that leave patients disabled. The C3-C3aR bridge explains amplification — the astrocyte calls in the microglial response [1][5].
The experimental design is unusually thorough for a mechanistic paper: two different animal models (a local eye model and a systemic motor model), two levels of intervention (receptor inhibition and downstream STAT3 inhibition), and functional readouts rather than histology alone [1][2].
What stands between this and a treatment
Complement is not a neutral target. C3aR blockade could reduce the tissue-damaging arm of complement while leaving host defence against infection partly intact, which is why the receptor is more attractive than wholesale complement depletion [1][5].
The inhibitor used, SB 290157, is a laboratory tool rather than a clinical drug, and rodent models of NMOSD reproduce attacks but not the years of accumulating disability that define the human disease. Established therapies — complement inhibitors and IL-6 blockade — already prevent attacks effectively, so a new agent would have to show benefit in patients who still relapse, or a better safety profile, rather than simply activity in a model. No human dosing, pharmacokinetics or trial is reported [2][5].
The condition in context: NMOSD
It is a rare disease with high relapse and disability rates, and treatment is overwhelmingly prophylactic immunosuppression.
| Region | What the data shows | Source |
|---|---|---|
| Who is affected | Predominantly young women of Asian descent; added to China's first rare disease list in 2018 [2]. | SYSU Third Affiliated Hospital [2] |
| Burden | Repeated attacks cause significant motor and visual disability [2]. | SYSU Third Affiliated Hospital [2] |
| Treatment gap | Clinical options are limited and centred on immunosuppression [6]. | SYSU Third Affiliated Hospital neurology [6] |
Because each attack can leave permanent deficit, preventing amplification early in an attack is where a mechanism-targeted drug would have most value [1][2].
Why it matters
| Potential | What the report suggests | Source |
|---|---|---|
| Mechanism | A clear astrocyte-to-microglia relay [1][5]. | [1][5] |
| Functional rescue | Improved vision and movement in models [1]. | [1] |
| Caution | Tool compound only; no human data [2][5]. | [2][5] |
Availability and limits
- This is an editorial summary of a research paper, not a treatment recommendation [1][2].
- No clinical trial of C3aR blockade in NMOSD exists [5].
- Animal models do not capture chronic human disability [2].
- Established preventives remain standard of care [6].
- Complement-targeted drugs already exist for this disease, raising the comparative bar [5].
What to ask before booking
| Question | Why it matters |
|---|---|
| Is my AQP4 antibody status confirmed? | It defines the disease and treatment choice [2]. |
| Am I on an attack-prevention therapy? | Prevention is the established standard [6]. |
| Which department handles foreign patients, and in what language? | The hospital is a working hospital we do not book; confirm international-department coordination and language support. |
| Are any trials of complement or C3aR agents open? | None is reported from this work [5]. |
Questions patients ask
What was found?
NMO-IgG makes astrocytes secrete C3, which upregulates C3aR on microglia and activates STAT3, amplifying neuroinflammation; blocking C3aR improved visual and motor function in animal models [1][5].
Where was it published?
Fundamental Research, on 18 November 2025 [1][2].
Is there a drug?
No — the inhibitor used is a laboratory tool compound, with no human data [2].
Why does it matter clinically?
It identifies an amplification step that could be targeted during attacks, beyond broad immunosuppression [1][2].
Is this relevant to international patients?
It is useful context for China's neuroimmunology research. The hospital is a working hospital we do not book — contact its international department directly [1].